IN2014DN00254A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00254A
IN2014DN00254A IN254DEN2014A IN2014DN00254A IN 2014DN00254 A IN2014DN00254 A IN 2014DN00254A IN 254DEN2014 A IN254DEN2014 A IN 254DEN2014A IN 2014DN00254 A IN2014DN00254 A IN 2014DN00254A
Authority
IN
India
Prior art keywords
compositions
treatment
invention include
include methods
adipose deposits
Prior art date
Application number
Other languages
English (en)
Inventor
Katherine Cernok
Kenneth Martinez
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014DN00254A publication Critical patent/IN2014DN00254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
IN254DEN2014 2011-07-20 2012-07-19 IN2014DN00254A (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509700P 2011-07-20 2011-07-20
PCT/US2012/047405 WO2013013042A1 (en) 2011-07-20 2012-07-19 Botulinum toxins for use in a method for treatment of adipose deposits

Publications (1)

Publication Number Publication Date
IN2014DN00254A true IN2014DN00254A (hu) 2015-06-05

Family

ID=46601917

Family Applications (1)

Application Number Title Priority Date Filing Date
IN254DEN2014 IN2014DN00254A (hu) 2011-07-20 2012-07-19

Country Status (12)

Country Link
US (1) US20140127188A1 (hu)
EP (1) EP2734224A1 (hu)
JP (1) JP2014520892A (hu)
KR (1) KR20140082956A (hu)
CN (1) CN103702681A (hu)
AU (1) AU2012283968B2 (hu)
BR (1) BR112014001066A2 (hu)
CA (1) CA2841955A1 (hu)
IN (1) IN2014DN00254A (hu)
MX (1) MX2014000612A (hu)
RU (1) RU2014103543A (hu)
WO (1) WO2013013042A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9655926B1 (en) 2013-08-23 2017-05-23 Amiya Prasad Treatment for hair thinning and hair loss
WO2016021985A1 (ko) * 2014-08-07 2016-02-11 김상덕 보툴리눔 독소와 공기의 혼합물을 포함하는 안면 윤곽 교정용 조성물 및 이를 이용한 안면 윤곽 교정 방법
CN108431013B (zh) 2015-12-18 2021-03-16 美国陶氏有机硅公司 二硅烷基胺和聚硅烷基胺的合成
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
CN110996979A (zh) * 2017-05-18 2020-04-10 雷文斯治疗公司 颈肌张力障碍的治疗方法
US20190030118A1 (en) * 2017-07-27 2019-01-31 Ipsen Biopharm Limited Treatment of lower limb spasticity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE292977T1 (de) 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
ES2385130T3 (es) 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7288259B2 (en) * 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
US7727537B2 (en) * 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
TR201901443T4 (tr) * 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemülsiyonları.
WO2009026949A1 (en) * 2007-08-31 2009-03-05 Dsm Ip Assets B.V. 4-amidino benzylamines for cosmetic and/or dermatological use
US20090297632A1 (en) * 2008-06-02 2009-12-03 Waugh Jacob M Device, Methods and Compositions to Alter Light Interplay with Skin
WO2009158687A1 (en) * 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
BRPI1007812B1 (pt) * 2009-03-02 2017-09-26 Doris Maria Hexsel Lipoatrofia cosmetic medicinal

Also Published As

Publication number Publication date
KR20140082956A (ko) 2014-07-03
RU2014103543A (ru) 2015-08-27
US20140127188A1 (en) 2014-05-08
AU2012283968B2 (en) 2016-04-14
JP2014520892A (ja) 2014-08-25
CA2841955A1 (en) 2013-01-24
WO2013013042A1 (en) 2013-01-24
EP2734224A1 (en) 2014-05-28
BR112014001066A2 (pt) 2017-02-21
CN103702681A (zh) 2014-04-02
MX2014000612A (es) 2014-02-27
AU2012283968A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
IN2015DN00127A (hu)
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
PH12015500525A1 (en) Formulations of enzalutamide
GB201103062D0 (en) Method
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
IN2014CN04765A (hu)
MX355728B (es) Inhibidores de cinasas.
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
MX2013007168A (es) Anticuerpo anti-pcsk9 y metodos de uso.
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
IN2014CN03555A (hu)
IN2014DN00254A (hu)
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
IN2014CN04634A (hu)
IN2014DN09450A (hu)
IN2013MU00848A (hu)
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
IN2014CN00312A (hu)
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.